Ovarian-Cancer-Drugs-Market-

Ovarian Cancer Drugs Market To Witness Robust
Expansion By 2026
Ovarian Cancer Drugs Market - Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018-2026
Ovarian cancer is one of the most dreadful type of cancer widely found in women. In this cancer,
abnormal cells growth is experienced in the ovaries, which has potential to invade or adversely affect
other body parts such as abdomen layers, lining of the bowel and bladder, lymph nodes, and liver.
Initial stages of ovarian cancer are associated with few vague symptoms, which further manifest as the
cancer grows. These symptoms include inflating, pelvic ache, abdominal puffiness, and loss of appetite.
Request For Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/164
Ovarian cancer is a relatively rare cancer as compared to other types, though risk is higher among
women who have ovulated more over their lifetime, which can also include females who have never
borne a child and those who began ovulating at a very young age. According to American Cancer
Society, around 10% of ovarian cancer cases are related to inherited genetic risk. Women with

mutations in BRCA1 or BRCA2 genes have 50% chance of developing breast or ovarian cancer.
Ovarian carcinoma, is the most common ovarian cancer that accounts for 95% of cases, globally.
Ovarian cancer drugs market supported by growing aging population in the U.S. and U.K.
Rising number of ovarian cancer cases recorded over the recent past, is creating a highly conducive
environment for growth of the ovarian cancer drugs market. According to American Cancer Society, in
2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S.
According to the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer
Institute data, an increase in all new cancer cases is recorded, with ovarian cancer accounting for 1.3%
of the incidence rate, and 2.4% of all related deaths, in 2016. The number of new ovarian cancer cases
account for 11.9 per 100,000 women, and the total deaths account for 7.5 per 100,000 women,
annually.
According to World Cancer Research Fund International data on the basis of highest rate of ovarian
cancer by country: Fiji, age standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria with
age standardized rate per 100,000 being 14.2 and 14.0, respectively. The U.K. stands tenth, with age
standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in
emerging economies, with the highest incidence rate recorded in Africa and Asia Pacific. In the U.K.,
around 46% of women diagnosed with ovarian cancer, survive for around five years or more following
the onset of the disease.
Combinational drug approach, a novel approach in the ovarian cancer drugs market
Key players operating in the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli
Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech
Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd. Major
companies in this market are constantly working towards introducing innovative products and lowering
production costs in order to enhance profitability. For instance, Roche’s blockbuster drug Avastin
(bevacizumab) used in combination with carboplatin and paclitaxel is being used to treat ovarian
cancer.

Current scenario in ovarian cancer drugs market: High prevalence of ovarian cancer among
women over 60 years in the U.S. and U.K.
Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights
comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North
America accounts for the largest market share, mainly due to presence of major players and adoption of
advanced medical technologies in countries such as the U.S. and Canada. According to American
Cancer Society, an estimated 22,440 women would receive a new diagnosis of ovarian cancer and
around 14,080 women will die from ovarian cancer in 2017 in the U.S. alone. Click to Read More On
Ovarian Cancer Drugs Market.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com